J Clin Lipidol
-
Randomized Controlled Trial
Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
Patients with metabolic syndrome (MetS) are at increased risk for cardiovascular disease. Niacin improves lipid abnormalities associated with MetS, but is underused, mainly because of flushing. Laropiprant (LRPT) reduces niacin-induced flushing and, in combination with extended-release niacin (ERN/LRPT), improves lipid levels. ⋯ In patients with MetS, ERN/LRPT improves multiple lipid parameters associated with increased cardiovascular disease risk. ERN/LRPT numerically improved triglyceride levels more in patients with versus without MetS, which is likely related to greater baseline triglycerides in MetS patients.
-
Randomized Controlled Trial
Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
To evaluate the safety profile of extended-release niacin/laropiprant (ERN/LRPT), pooling data from studies in the clinical development program. ⋯ The favorable safety and tolerability profile of ERN/LRPT for up to 1 year supports the use of LRPT to achieve improved therapeutic dosing of niacin, an agent with comprehensive lipid-modifying efficacy and shown to reduce cardiovascular risk.
-
Hyperlipidemia is a significant, modifiable risk factor for developing coronary heart disease. Low-density lipoprotein cholesterol (LDL-C) goal achievement has improved overall, but many high-risk patients remain above the desired LDL-C goals. Published data have demonstrated the ability of pharmacist-managed lipid clinics to improve lipid management in a variety of clinical settings. ⋯ An outpatient hospital-based, pharmacist-managed lipid clinic improved LDL-C goal attainment. Our results are unique in that pharmacists used point-of-care testing to obtain lipid results for making therapy adjustments during the face-to-face visit.
-
Beta-thalassaemic patients who usually have a combination of; chronic hemolytic anemia, iron storage disease, myocarditis, and premature death especially due to heart failure may also have increased oxidation of lipids and abnormal lipoprotein concentrations. ⋯ Despite the derangement in plasma lipid profile in children with β-thalassemia accompanied by excess lipid peroxidation, the lipoprotein concentrations do not suggest increased risk. The MDA/LDL-C ratio may prove to be a valuable marker for lipid peroxidation.